Background & aim: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). Importantly, semaglutide was recently approved as the first GLP-1-based treatment for people with MASH with moderate-to-severe fibrosis. Translational models that recapitulate…
Background & aim: Glucagon influences kidney function through both direct intrarenal glucagon receptor (GCGR) signaling and indirect humoral pathways. Increasing evidence suggests that renal GCGR activity is impaired in chronic kidney disease (CKD). Survodutide is a novel, long-acting dual GCGR/GLP-1…
Background & aim: Long-acting amylin analogues offer mechanistic complementarity to incretin-based therapies for obesity. Accordingly, CagriSema, a fixed-dose combination of the amylin analogue Cagrilintide and the GLP-1 analogue Semaglutide, has demonstrated superior weight loss compared with either agent alone in recent clinical trials…
Background & aim: Classification and counting of ovarian follicles is a key endpoint in preclinical models of reproductive disorders. Traditionally, this relies on manual histopathological scoring subjecting to inter- and intra-observer variability, thus affecting reproducibility. This study aimed to validate GHOST (Gubra…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX) is a long-acting FGF21 analogue currently in phase 3 clinical…
Background: Injectable peptide-based glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RAs) are effective treatments for obesity and diabetes but are limited by patient compliance and scalability challenges. In contrast, non-peptide small-molecule GLP1RAs offer the advantage of oral delivery but are relatively inactive…
Background & aim: Polycystic ovary syndrome (PCOS) affects approximately 10–15% of women of reproductive age and is a leading cause of anovulation and infertility. PCOS is frequently accompanied by hyperandrogenism, insulin resistance, and altered body composition. Androgen-induced mouse models reproduce…
Background & aim: Subcutaneous pump delivery of the GLP1-receptor-agonist exenatide reduced body weight and improved glycemia in the DIO mouse. Basal-bolus administration conferred advantage over basal alone. This mode of incretin-based therapy offers an alternative to conventional intermittent dosing and…
Background & aim: The current understanding of diabetic kidney disease (DKD) has significant gaps regarding the underlying pathogenesis. In this study, we aimed to characterize the temporal progression of DKD using a state-of-the-art mouse model of hypertension-accelerated disease, integrating kidney…
